SVOPL Inhibitors
SVOPL inhibitors are a class of molecules specifically designed to interact with a certain type of protein known as SVOPL. The design process of these inhibitors is a complex endeavor that requires a detailed understanding of the structure and function of the SVOPL protein. Scientists employ advanced techniques to ascertain the three-dimensional configuration of the target protein, which is crucial for crafting molecules that can effectively bind to it. The specificity of SVOPL inhibitors is a result of meticulous molecular engineering to ensure that these molecules fit snugly into the active site of the SVOPL protein, much like a key fits into a lock. This high level of specificity aims to ensure that the inhibitors interact primarily with the SVOPL protein and not with other proteins, thus minimizing off-target effects.
The synthesis of SVOPL inhibitors is a sophisticated process that encompasses various stages of chemical development. It involves the construction of complex organic molecules through a series of reactions that introduce the necessary functional groups and build the molecular framework conducive for interaction with the SVOPL protein. After synthesis, the molecules undergo a battery of biochemical assays designed to confirm their ability to bind to the target protein and to assess their efficiency. The development of SVOPL inhibitors is not only a reflection of the progress in chemical synthesis techniques but also represents the convergence of multiple scientific disciplines, including structural biology and computational modeling, to achieve a precise interaction with the biological target of interest. This process exemplifies how a deep understanding of protein structure and function can lead to the creation of highly specific molecules with the ability to modulate protein activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which subsequently inhibits the ERK pathway. SVOPL is indirectly inhibited as this pathway is crucial for the phosphorylation and activation of certain proteins that may interact with or regulate SVOPL function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the AKT signaling pathway. Inhibition of PI3K leads to reduced AKT activation, which can influence the cellular processes that SVOPL might be involved in, particularly if SVOPL function is tied to AKT-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. This kinase is involved in response to stress and inflammatory cytokines. SVOPL activity could be modulated by p38 MAPK, and inhibiting this kinase could lead to a decrease in SVOPL's functional activity if it is part of the stress response signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that blocks the ERK pathway. By impairing this pathway, proteins that are downstream or that interact with the ERK pathway might be affected, including SVOPL if its function is modulated by ERK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible PI3K inhibitor. Inhibition of PI3K leads to a decrease in downstream signaling, including the AKT pathway, potentially suppressing the cellular activities in which SVOPL is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is essential for cell growth and proliferation, and by inhibiting this pathway, the function of SVOPL could be indirectly affected if it is linked to these cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK family. JNK signaling is implicated in various cellular processes, including apoptosis and inflammation. Inhibition of JNK could potentially decrease SVOPL functional activity if it is involved in JNK-related pathways. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 0796 is a selective inhibitor of p38 MAPK isoforms. By blocking p38 MAPK activity, it could lead to a decrease in SVOPL activity if SVOPL's function is regulated by or dependent on the p38 MAPK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases are involved in various signaling pathways that could regulate SVOPL activity, and inhibition of Src could lead to decreased SVOPL function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of proteins. By inhibiting the proteasome, proteins that regulate SVOPL stability or activity might accumulate, leading to altered SVOPL activity. | ||||||